TRANSKRIP 🔗
Communicable 067: Antifungal pipeline
===
[00:00:00]
Annie: Hello, and welcome back to Communicable, the podcast brought to you by CMI Communications, ESCMID's open access journal covering infectious diseases and clinical microbiology. My name is Annie Joseph. I'm a clinical microbiologist at Nottingham University Hospitals NHS Trust in the UK and associate editor at CMI Comms.
I'm really happy to be joined today by my co-host, Josh Nosanchuk, fellow editor at CMI Comms, infectious diseases clinician, medical mycologist, and Dean of the Covenant Healthcare College of Medicine at Central Michigan University in the US. Hi, Josh.
Josh N: Hi, Annie. I'm really excited to be co-hosting this with you.
We're really excited to be welcoming two outstanding guests today to discuss what's happening in our antifungal pipeline. The first is my US-based medical mycology pal, Jeniel Nett. Jeniel is a professor [00:01:00] of infectious diseases at the University of Wisconsin at Madison, where she is also a senior leader of their medical school's Medical Scientist Training Program.
In addition to serving on committees for the NIH, CDC, and the Infectious Disease Society of America, Jeniel is the director of the world-renowned Woods Hole Molecular Mycology course. Jeniel, welcome to Communicable.
Great. Thanks. Happy to be here. Thank you for the introduction, Josh.
Josh N: And our second guest, Neil Stone, has worked in the UK and across the African continent, and currently is a clinical scientist in infectious diseases and microbiology at the Hospital for Tropical Diseases and holds a post at the University College London.
Neil, our editor-in-chief, Angela Huttner from the University of Geneva, told us that you're a fun guy who would absolutely rock this episode of Communicable. So I guess, Jeniel, this makes you the fun gal. Anyway, thank you for joining us.
Neil: It's great to be here. Thanks, for inviting me and glad to be back on Communicable.
I love [00:02:00] that joke. I always try and hope someone gets that into any talk about mycology, so well done, Josh.
Annie: Let's see how many fungal puns we're going to manage to squeeze into one episode. so as our listeners know, we always start these episodes with a get to know you question and, our hosts go first so guests don't have to.
so here it is. what was the coolest thing that you saw this summer? Josh, you get to go first.
Josh N: thank you, Annie. I was really fortunate to be celebrating a big birthday with a zero, and my wife arranged for us to go up to Alaska. And we were out on the water and we saw a pod of humpback whales bubble feeding.
So they dive down, they blow bubbles, they come up and they have this feast and it is the most impressive activity, these enormous mammals, right near you and the sound and the power was just incredible.
Annie: That sounds very cool, Josh. Mine is not as exciting. I spent the summer in France on holiday [00:03:00] and, we were in the Loire Valley visiting lots of different, chateaus.
We went to one chateau, Chateau de Villandry, and the gardens were designed in, multiple squares, and each square had a different design, and every square represented a different kind of love. So apparently, hundreds of years ago when they built the chateau, you could communicate your feelings to your suitors by choosing which square you were going to have your afternoon walk in or sit in the gardens of, and that would be like a secret little message sent to your suitor or your lover, which made me really think about how our communication nowadays is just so, instantaneous.
But it wasn't that long ago where you had to, wait to grow the whole garden first before you could communicate your feelings. so that was the coolest thing that I saw, quite quiet and sedate. Jeniel, what about you?
Jeniel: Uh, one of the coolest things I saw was, the Birch Aquarium in San Diego, California.
I was attending, the Neutrophil International Symposium, and the organizers had rented the aquarium for the conference, [00:04:00] so that attendees could watch the sunset over the Pacific Ocean, and then we could go in and explore the exhibits, in the evening. And there was so much wildlife to view.
The marine life was fabulous, and I thought the jellyfish were very cool
Annie: I like that. Conference at an aquarium, that is very cool. I think all conference organizers should be, taking note Neil
Neil: So the coolest thing I saw this summer was with my family. We visited the Lake District of England.
I It's in the northwestern corner of England. It's very rural and beautiful, and as it suggests, lots of lakes. And it's ... You know, I've lived in London now for a long time. It's good to get out of the big city and breathe.
so that was cool enough in itself, but we were walking around in this completely idyllic little village setting, extremely quiet, and all of a sudden there was a tremendous noise, and something dashed overhead, and it was a Typhoon fighter jet, and the Royal Air Force were doing a training program just nearby.
So my nine-year-old son especially thought that was extremely cool. So that was a highlight of the summer
That's cool. I do know the Lake District, Neil. I grew up in the Northwest. it [00:05:00] rains a lot. I've never seen the Typhoon fighter jets, but I've seen a lot of rain
Neil: It's a beautiful part of the world.
Annie: It is. thanks all for sharing. So now let's jump in for the topic of today's episode, antifungals and the antifungal pipeline. Neil, you care a lot about fungi. Can you tell us why we should care about fungi and why we need to be thinking about the antifungal armamentarium?
Neil: I'm probably preaching to the converted, but there might be people out there who still need some convincing that fungi are important.
And I'm sure all of you have come across this real perception that fungal infections are rare and benign, whereas in fact, they're very common and
Load full transcript
they're very deadly.
there was a recent estimate that fungal infections cause nearly four million deaths per year globally, which is obviously massive. That's more than, TB and HIV, combined, probably malaria as well. so it's been neglected for a long time because of this misperception that it's not important, but clearly it is and, we have to do something about it.
We've been left with this legacy of very few diagnostics, very [00:06:00] few treatments, which has made it very difficult to treat. Fortunately, things have changed though. the WHO have recognized this in the last few years. Just a little side story about the WHO. I think everyone is, I'm sure is aware of antimicrobial resistance and antibacterial resistance.
And the WHO, the World Health Organization, put out a priority pathogen list first in 2018. Very noble about the most important pathogens which need urgent research and investment into tackling, and it was a good list except for the fact they were all bacteria.
They forgot fungi completely, and that was just absolutely typical of mycology being left behind. It wasn't deliberate, they just forgot about it. But the great thing is the WHO actually, made up for that error, and in 2022 published the fungal priority pathogens list because there was a realization this is a huge problem.
It causes a massive amount of morbidity and mortality, and they needed to do something about it. So they put out this list with priority pathogens in it. Now, at the beginning, I was quite skeptical, and I thought, "Well, it's just [00:07:00] a list. What's a list going to do?" but actually that's been really important in driving forward the research agenda and getting funding and putting it out there because the, numbers really are staggering.
So besides the four million deaths nearly per year, going back to the idea that people think it's trivial, well, you know, skin and nail infections or oral thrush or vulvovaginal candidiasis, sure, they're not going to kill you, but they cause a massive amount of morbidity. we're talking hundreds of millions of cases Something like one in six people on the planet at any given time has a fungal infection of one sort or the other.
for example, with antifungal resistance even in the skin infections, we are talking about a public health problem on a massive scale. people are often amazed when I tell them these figures. They just had no idea that it was such a problem. And we're starting in a very difficult place with this legacy of under-investment, lack of research, and lack of diagnostics and treatments.
So that's kind of a brief overview of where we are. I think things are changing for the better. There are treatments and diagnostics coming through, and I think there's now a [00:08:00] realization, at least in the medical research community, that this is really a big problem and it's only getting bigger.
Josh N: thank you for that. and we have talked about the fungal priority pathogen list on Communicable
previously, but this is really important context, Neil. I'm going to turn to Janeil and ask her to give us an overview of the drugs that we usually are using to treat serious fungal diseases, and also what their limitations are.
The antifungals we generally, use belong to three main categories, polyenes, azoles, and echinocandins. So the polyene drug class first came to market in the late nineteen fifties and this class includes the various formulations of amphotericin B. So these act by binding ergosterol, and amphotericin B is broadly active against a variety of fungi and is currently recommended as first-line treatment for several severe in-invasive fungal infections.
these include those caused by Cryptococcus, Blastomyces, Histoplasma, and Coccidioides, as well as neonatal candidiasis. However, amphotericin B, [00:09:00] it has a lot of drawbacks as many, who use this, antifungal know. It is only available IV, and it can cause, several side effects, that include infusion reactions, electrolyte disturbances, and kidney toxicity. There are liposomal formulations, that have fewer of these side effects, and they're often used in adults. However, even with those formulations, we see that the side effects can limit treatment.
in the nineteen eighties, we saw the introduction of azole drugs. These act by inhibiting ergosterol production, and they have both oral and IV formulations. Fluconazole is often used for the treatment of mucosal candidiasis, and for more mild cases and step-down therapy for infections caused by coccidioides, candida, and cryptococcus.
Jeniel: Another azole, itraconazole, is similarly used to treat Blastomyces and Histoplasma. And then some of the newer azoles, voriconazole, posaconazole, and isavuconazole, are used for the prevention and treatment of fungal pneumonias caused by Aspergillus and other filamentous fungi. the main side effects of azole drugs [00:10:00] are drug interactions and liver toxicity.
Some also require monitoring of serum drug levels. A more recent drug class is the echinocandins, and these inhibit cell wall beta-glucan synthesis. They're only available as IV formulations. They're primarily used for the treatment of invasive candidiasis, but they have, few, drug interactions and side effects
Annie: Thanks, Jeniel. That's a great overview of, what we've already got in the toolbox for, treating fungal infections. we've really got a handful of drugs, and we've had a handful of drugs for decades really, which has been part of the problem.
so we have got some newer antifungals that have been approved, recently, which is very exciting. And hopefully, we'll be able to, bring these sort of more into our routine clinical practice. So for example, we've got ibrexafungerp which is a novel oral triterpenoid, first approved in 2021, but has limited availability at the moment in most locations.
and also, rezafungin, which is a [00:11:00] long-acting echinocandin, from 2023. So Neil, can you tell us a little bit more about these two drugs and any others that have been recently approved as well?
Neil: Thank you, Annie. So first thing to say is just how few drugs we have and also Jeniel going through them.
Only got three classes that we have for invasive fungal infection, and only two targets really, the cell membrane and cell wall. ibrexafungerp and razafungin are, are really interesting drugs. Firstly, the names are absolute tongue twisters. Razafungin's a bit easier than ibrexafungerp.
Neil: I don't know what they were smoking when they came up with the name ibrexafungerp. anyway, that's what it's called. so starting with ibrexa, I think I'm going to call it for short. So it works in a very similar way to the echinocandins.
So the echinocandins, as Jeniel mentioned, they've been widely used for a couple of decades now, particularly in Candida infections, highly active. and they e-effectively act on beta-glucan synthase to disrupt cell wall synth-synthesis, and they're very effective and fungicidal. ibrexafungerp belongs to this triterpenoid class, which is very similar to the echinocandins, just act on [00:12:00] a slightly different binding site to the beta-glucan synthase.
But it's, all intents and purposes, I would say, the same mechanism of action, just with that very slightly different binding site. The really important difference compared to the other echinocandins is that it's orally bioavailable, and that's critically important because the current echinocandins that are widely used, which are caspofungin, anidulafungin and micafungin, all of which are very similar in their spectrum of activity, and side effect profile and pharmacokinetic, pharmacodynamic profile.
They're all given IV only. So to have an orally available drug which is very similar to an echinocandin is, hugely important. The spectrum of activity is very similar to the echinocandins, essentially a very, very good anti-Candida drug. and that's probably going to be the main indication for it.
It has been licensed in the US, I believe, for vulvovaginal candidiasis. And it comes under the brand name Brexafemme. it was basically FDA approved [00:13:00] based on a phase three, randomized controlled trial, which is named, the Vanish trial back in 2021. Bit of a controversial trial, I have to say, va-vulvovaginal candidiasis, as I mentioned enormously common, not deadly, but causes a lot of misery and is very unpleasant. So a good indication, I think, especially for oral outpatient treatment.
It was actually tested against placebo, which is an interesting ethical, trial design. and that raised some eyebrows. But anyway, that was thought to be acceptable by the regulators and went through and was found to be more effective, certainly than placebo for vulvovaginal candidiasis, and got its license based on that.
But you can imagine that you might be able to replace, at least in theory, an IV echinocandin for an oral triterpenoid, which as I mentioned, it's got good oral
bioavailability, almost identical spectrum of action to the echinocandins. And for example, step-down therapy perhaps for invasive candidiasis.
it's also got activity against some of the more resistant candida species, which are often fluconazole resistant. For example, Candida glabrata, which is now called [00:14:00] Nakaseomyces glabratas. Even Candida auris, which I've not mentioned yet that multi-drug resistant candida species, which is causing a lot of problems.
So to have an oral agent is really, really great. There's one big problem with ibrexafungerp right now clinically, is that, certainly for me anyway, and I don't know about my colleagues here who are working in the US, I can't get hold of it. as far as I'm aware, there's, been, manufacturing issues.
Neil: it's just not available despite the fact that it is licensed in the US. And I don't know if Josh or Jeniel I've actually not managed to prescribe it at really any point. So we could talk, until the, sun goes down about what a fantastic drug it might be.
But if we can't get hold of it, that's obviously a real limitation.
I think we would all love it to, because to have essentially an oral echinocandin would be a huge advance, in medical mycology.
Josh N: Yeah. So I've, only used it once, and there was a manufacturing issue, like you were saying,
so it's considered temporarily unavailable, unfortunately.
we've had a couple of patients where we've really come to the end of the line with [00:15:00] various antifungals for different reasons and sort of made inquiries about getting hold of it and always been told, currently no manufacturing and not been able to get a hold of it.
Annie: But I think it's really interesting. I wonder whether this will happen with some of the other antifungal drugs that the license indication is, really not what we're all holding on for. licensed for vaginal candidiasis but, in an ideal world, if we had good availability, I'm sure we'd probably be using it for very different indications than that.
Jeniel: Yeah.
I similarly haven't been able to get ahold of it recently. but I, was, able to, prescribe it for several patients with, vaginal candidiasis due to resistant organisms. Um, and it was, effective then. one thing I also wanted to point out is when we were talking about using it for, vaginal candidiasis or recurrent candidiasis versus one of, these more serious, indications like an invasive infection, is that I believe they were studied at different doses.
And I don't know if it would be easy to be able to use the lower dose, , for an invasive infection and whether or not they're going to make, , the higher dosage and continue making it at all
Annie: Yeah, that's a good [00:16:00] point.
Neil: we can all think of indications where we would like to use it or at least should be trialed.
As I've mentioned, step-down therapy for invasive candidiasis, prophylaxis in hematology, for example, in patients who can't tolerate azoles perhaps or, polyenes. all of us, in the mycology community would really like to see this taken forward, but of course there are commercial considerations, and, industry considerations which we, we really have no control of.
Sometimes we are at the mercy of pharma companies where, if they don't see a commercial future for it, they're just going to ditch it, which I think would be a terrible shame for mycology because, any new drug is welcome, but especially an oral echinocandin would be a real, improvement in what we have already.
Neil: So I really hope that's resurrected and taken forward to further trials. even for recurrent vulvovaginal candidiasis, I do see increasing numbers of patients with this problem, and it can be very, very difficult. we've only got azoles as a systemic oral antifungal for a lot of these infections.
And just to have another option, would really be great, . So that's it, ibrexafungerp. I, hope there's more to come on [00:17:00] that drug.
Josh N: Yeah. and what's interesting is that even though it targets the beta 1,3-D-glucan synthase, it does it slightly differently than the echinocandins.
And, and I think that needs to be emphasized, because as you pointed out, the drug resistance issues, and I'll just give a shout-out to Jeniel who works on Candidozyma or Candida auris and has done some beautiful work in that space
Neil: Yeah. most of the auris strains, at least that we see are echinocandin susceptible, but also triterpenoids, ibrexafungerp in vitro has really good activity against most Candida auris clinical isolates that have been tested.
So, we need all the agents we can get for that particular beast, which is also something I'm, working on as well. and it'd be a real shame to lose that. I think just before move away from i- ibrexa maybe, and just talking about vulvovaginal candidiasis, there's just a really interesting drug to mention cause we're talking about drugs which, which have actually been licensed now and are really towards the end of the pipeline.
It's It's osteoconazole, brand name Vyvjoa. again, that has been licensed based on, phase three randomized controlled [00:18:00] trials, again in vulvovaginal candidiasis, which are often done because it's common, it can be done in outpatients, so it's easier to do studies on. that's a really interesting drug. So it's an azole antifungal, so it's not a new mechanism.
Also targets, ergosterol synthesis, targeting erg11 in Candida. What's really interesting about it is its pharmacokinetics, because it's got extremely long half-life of weeks and weeks and weeks So in theory, , you could give them, , perhaps one or two doses or weekly dosing or even monthly dosing and highly, highly effective.
But again, it just seems to have disappeared because of manufacturing or industry issues. Really interested to hear if you've been able to get a hold of that drug, osteoconazole.
Jeniel: I've been interested in this drug. with this, long half-life, and it was very
effective for a recurrent vaginal candidiasis.
the issue that we've really had with it is it's not recommended for women of reproductive potential. And so of the people I see with recurrent vaginitis, it's something that I'm not able to really prescribe for them, because almost all of them are of reproductive potential.
So I [00:19:00] actually haven't prescribed this drug.
Josh N: it's also important to realize that some of the even more common drugs are not always available globally. There are countries like Brazil which have now made many of these antifungal drugs a required availability. But even if they are, quote-unquote, available, sometimes because of distribution, storage, they're not available everywhere.
And now we're talking about drugs that are really at the cutting edge. And I just want to point out that infectious diseases has an inequity, globally, and it gets to what Neil said earlier about them being neglected. So I think that's something that we should talk about more maybe on another episode of Communicable
Neil: yeah, just to say, Josh, I think it's a great point about accessibility and equity because, it's great talking about these new drugs and it's fantastic but, we can't get amphotericin B in certain countries. We can't get flucytosine particularly in the African continent, which is hardest hit by, for example, cryptococcal meningitis.
So access is a huge issue, but perhaps that's for another, episode.
Josh N: Yeah. Another aspect of this is whether labs are [00:20:00] routinely doing susceptibility testing for these newer drugs and, that doesn't always seem to be the case.
In fact, mostly they don't. Do you folks in the UK do susceptibility testing for things like ibrexa?
Neil: Certainly not routinely. So we have difficulty getting antifungal susceptibilities in general, for the standard agents, never mind the new ones. So in general, we don't. So even rezafungin, that's also an issue.
Rezafungin is a very interesting drug. This has now been, licensed certainly in the UK, also in the US and other countries around the world. It's a novel echinocandin.
It's very closely related to anidulafungin. So anidulafungin's been used for 20 years plus now. it's so-called anidulafungin because it's derived from Aspergillus nidulans. I always like drug origin names. I don't know how they chose the name rezafungin. It's just got a slightly different, change to the molecule which changes its pharmacokinetics significantly.
And the key difference it is from any other echinocandin is that it can be given weekly, which is really important. We get a very, very high peak initially with the [00:21:00] initial dose and it just gradually is cleared over time. But it remains above clinically relevant MICs for certainly more than a week.
And that's what's really revolutionary about it. Yes, it's still IV, but it's once a week compared to all the other echinocandins we have so far, which are daily. it's been licensed now really on
the basis of, two key trials.
Neil: There was, initially STRIVE, which was a phase two dose-finding trial, but then RESTORE, which was a head-to-head randomized controlled trial against caspofungin as first-line therapy for invasive candidiasis. That's either candidemia, most of the cases were Candida in the bloodstream, but also other cases of invasive candidiasis, which were blood culture negative, for example, abdominal candidiasis.
. That was a non-inferiority study. It met the predetermined non-inferiority endpoint. They weren't trying to show superiority because with non-inferiority they have the added advantage of, once a week dosing.
Side effects for profile spectrum activity all seems very, very similar [00:22:00] to the echinocandins that we've been very used to using for a long time. So really what's happening now is we're, just trying to find out where this is going to fit essentially. The next stage in development of this drug is prophylaxis as well the company who, have been developing this, have just completed a phase three randomized controlled trial in, allogeneic stem cell transplant, people with hematological malignancy called the RESPECT trial.
So the paper's not been published. I know the headline result has been put out by the drug company, which showed that it was non-inferior to, standard of care, which was mostly fluconazole, which is interesting because that's not mold active. Some were posaconazole, but not, not many. And cotrimoxazole, Bactrim or Septra, because one of the endpoints was PJP prophylaxis as well.
You can get breakthrough PJP infections. So we've not seen all the details yet. We await the peer-reviewed study, but the headline is that it's non-inferiority as well. it's not yet licensed for that indication. I suspect it will be. It's [00:23:00] currently licensed for treatment of invasive candidiasis, but it can be given once a week.
And that's really, really a great addition. We occasionally have patients who need long-term echinocandin therapy, for example, with complex candidiasis, whether it's, spinal Candida osteomyelitis or Candida septic arthritis, for example, or hepatosplenic candidiasis, which needs long courses of anti-Candida treatment.
They can't use azoles for any number of reasons, whether it's drug resistance, which we're increasingly seeing, drug-drug interactions, toxicities. So instead of having to go to, liposomal amphotericin B, Ambisome, in an ambulatory setting, which is at least three times a week or at best two times a week, or daily echinocandin, which is a real burden for patients, we've now got this once-a-week option.
And I think that was interesting enough for treatment, but I think it's even more interesting for prophylaxis, again, for those patients who are unable to tolerate azole prophylaxis, and perhaps live, live a distance away but [00:24:00] just need to come to the hospital once a week, could even be de-delivered at home potentially.
So a very interesting new
drug. Completely revolutionary pharmacokinetics in terms of anything that we've really seen before, certainly with an echinocandin.
At the end of the pipeline Randomized controlled phase three double-blind placebo trials, which are extremely hard to do in mycology. And we've now got that data. Uh, we're just going to figure out how to use it. It's going to have its limitations. So echinocandin doesn't have a perfect spectrum of activity.
Neil: For example, it's not active against the Cryptococcus. It's not active against mucormycosis, so not active against the dimorphic fungi, the endemic mycosis. But I think for Candida infections, especially for prophylaxis, now it's going to be really important. I would add that we've used it for, Candida endocarditis longer-term treatment. It really is a wonderful thing to have as an available drug. I'm going to just jump forward into the pipeline.
Josh N: Jinyell, I know you've written about fosmanogepix in terms of Candida and Candida auris and other [00:25:00] pathogens. what can you tell us about this first-in-class drug?
Jeniel: Yeah. Fosmanogepix is an antifungal in an entirely new drug class. it inhibits fungal GWT one, which blocks GPI anchor biosynthesis.
and ultimately it inhibits mannoprotein production. And it was granted orphan drug fast track status for the treatment of invasive fungal infections by the FDA in the United States. Because of its new mechanism of action, it is active against many drug-resistant fungi.
Jeniel: So it's currently only available through emergency or expanded access programs. Those started around 2020. It exhibits activity against Candida, including Candida auris, Aspergillus, Fusarium, Scedosporium, Coccidioides, Cryptococcus, and some Mucorales. So really broadly active. And the, Candida auris has low MICs.
It has been found to be safe, and well-tolerated and efficacious, for candidaemia in a phase two study. And it's currently in, two phase three studies now. One is for invasive [00:26:00] candidiasis and one for invasive mold infection. So in the candidiasis study, they're comparing IV fosmanogepix, with oral step-down therapy with the same drug, because this drug is available both as IV and oral.
And then it's being compared to the standard of care, which in the study is caspofungin, with an option to switch to fluconazole step-down. for the invasive mold, phase three study, it's looking for, patients with invasive mold infections caused by Aspergillus, Fusarium, Lomentaspora, or Mucorales.
And there are two cohorts. One is randomized against standard of care, which is liposomal or azole. the other cohort is an open label salvage therapy design. One exciting thing about fosmanogepix is that it has good CNS penetration, so it was found to be effective for the treatment of Coccidioides for patients who had no other options, were not able to tolerate azoles.
and it was also used, for treatment of Fusarium meningitis in an outbreak in Mexico as, the isolates
of Fusarium causing the outbreak had [00:27:00] very high, MICs to other antifungals. There are some mild, side effects, related to gastrointestinal intolerance and elevated LFTs, but really seems to be, fairly safe and well-tolerated.
Yeah. So I think really this one's probably been the one we've all been keeping an eye on. although in my head I've been saying it completely different to how you've just said fosmanogepix out loud. I'm going to keep, that version in my head. but I think from the spectrum side of things, from the oral bioavailability and, penetration into different sites, I think it's really exciting and, we've not used this, yet in my center.
Annie: I don't know if you've got hold of it, used it for anything yet, Neil or, Josh?
Neil: with great difficulty. So I occasionally managed to get hold of it on com-compassionate use, but it was a bit of a struggle. but I have got hold of it. I, think I've used it once or twice. But yeah, also very interesting drug.
Oral, bioavailables is always really, really exciting, I think, because we are so few in mycology, and the spectrum is, really, really impressive, . So yeah, very excited to see the phase III trials [00:28:00] coming through,
Josh N: yeah, we've only used it a, few times at our institution, and, I was not involved in those cases.
it is really fascinating because they don't fully understand all the ways that this drug may actually work at the cell level. So there's a lot more research that will be done in the hopefully near future.
Annie: Fantastic. So, onto another novel compound with another unpronounceable name. So this one's olorofim. That's what I'm going with. so Neil, can you tell us a little bit about olorofim and, what this drug's all about?
Neil: So this is another really exciting new drug. And isn't it great that we're able to fill a whole episode with new antifungal drugs coming through, besides the fact that they're hard to pronounce.
if we did this ten, 15 years ago, we wouldn't have very much to talk about, I think. so it's really exciting. So olorofim, is a first in class drug, completely novel mechanism of action. As you'll recall, what we have at the moment, we only have two mechanisms of action is active against the cell membrane and the cell wall.
This is something called an orotamide, and it inhibits an enzyme called fungal dihydroorotate [00:29:00] dehydrogenase. that's a long way of saying that it's an enzyme which is responsible for de novo pyrimidine synthesis, and it blocks that essentially.
So what's important about this drug is it's an anti-mold agent. It does not have activity against yeasts. But when it comes to molds, it's, really, really impressive, at least in the lab. So Aspergillus, which of course are clinically most important mold globally. Some of the slightly rarer, but still challenging and relatively common molds that we see like Scedosporium, Lomentospora, very good activity in vitro, which is very exciting.
It's got some activity against Fusarium. Fusarium remains a real challenge across even these new agents. It's highly variable, . Might have some activity, but less convincing, but it's also really, really active, again in vitro against the dimorphic fungi or the endemic mycoses such as coccidioidomycosis, Histoplasma, Blastomyces.
Certainly, you know, Jeniel and Josh are probably more important where you work than where we work in the UK, Annie, but certainly I do see an increasing number of imported cases. And globally, these are very important infections certainly in vitro. [00:30:00] So what about in the clinical setting?
have been a couple of really important clinical trials coming through. So there was a large phase two trial, with over 200 patients with difficult to treat mold infections without other options.
Neil: generally the response rate was very good there. That was an open label, single arm, non-randomized trial. but they've just completed a trial called the OASIS trial, which is a phase three randomized trial head-to-head against ambisome for invasive aspergillosis And again, similarly to the, study, for prophylaxis for rezafungin, the paper's not been published, but the company has released its headline, result, that it was non-inferior to ambisone.
So we now have a drug potentially which is, really, really active against molds. It's given orally, not IV so far, which is an interesting problem. We love to have new oral drugs, but perhaps in someone's acutely ill in the throes of invasive aspergillosis when they're on ICU and then they'll have a transplant, will that be a problem?
Maybe not. That remains to be seen. And we all have to remember that if we're using this [00:31:00] drug for mold infections, we lose any yeast cover. So we don't have anything for Candida, which may be important in someone who's neutropenic, who might need to be on prophylaxis. So that's something to think about, but the headline figure certainly looks exciting that it's non-inferior to ambrisone.
So again, these are non-inferiority studies. showing they're as good as what we have with an added advantage. So olorofim has this advantage. It can be given orally. It's a new mechanism of action. It's got a really broad spectrum, and because of its new, completely novel mechanism of activity, you at least in theory, we're not seeing much drug resistance at all.
I think there are lots of other potential applications we could all think of where it might be used rather than just treating invasive aspergillosis. I've certainly used it, , off-label for patients within some of the endemic mycoses, which we see imported cases of who've been refractory to other therapies.
It seems to be very well-tolerated, some GI side effects, some liver function test arrangement, but rarely insurmountable.
Josh N: It's interesting, our, friend here in the US, G.R. Thompson, and other, folks published a [00:32:00] paper in Annals of Internal Medicine actually in September, so that's two
months ago. And they had only 41 participants. But they found that with disseminated coccidioides, and, I think it was two-thirds of them had brain involvement, which is incredibly difficult to manage.
They found that with olorofim they had success in, about 75% of the patients, which is really remarkable. And the other thing that was important there is, as you pointed out, some of the liver test abnormalities. About, one in five individuals had significant issues such that they had to change how the dosing was done, but they were still able to treat through that.
So really, for some of these diseases which nothing else has really worked for, , these are really incredible, medications. Now, there are only a handful of other drugs that are in advanced development as antifungals. one of the things that also is interesting, and it gets to even the issue of ibrexafungerp, is [00:33:00] how interested are pharmaceutical companies in developing some of these orphan drugs or drugs that are only going to be used for short periods of time.
But, I'm going to turn and ask Jeniel, what do you experience or have you experienced with trying to bring a new drug to market? And one of the drugs that I know you've been involved in and really David Andes at your institution is deeply involved in is a drug called turbinomycin. How have you seen that go from discovery from the deep sea to transition to future clinical use?
Jeniel: Turbinomycin is a very interesting, new antifungal. So it's discovered from the microbiome of a sea squirt. it has a novel mechanism of action that inhibits vesicle trafficking through Sec14. So this is a totally, new mechanism of action for an antifungal.
It has activity against Candida, uh, Candida auris, Aspergillus and Fusarium, and it also inhibits biofilms as well. there's some activity against Mucorales, but that's more variable. And so right now the [00:34:00] investigators here are looking at turbinomycin in preclinical studies, and they're also looking at, identifying analogs and finding ones that could maybe be moved forward.
So it's really, a new exciting antifungal but really in kinda early stages in preclinical development. But I certainly hope that it, is able to move, further.
Josh N: Well, it's great. You know, the other ones that are in development are things like GR-2397, NP-339 and MAT-2203 So I'm glad that you guys at least gave a name to the drug.
Annie: Yeah, I like a nice easy name to say and, also I, have no idea what a sea squirt is. Is it like a slug thing or something at the bottom of the ocean,
Josh N: yeah, the sea squirts are these really interesting animals that when they are disturbed or when you bring them up they, they spray out water and that's why they're called sea squirts.
But I think the more formal term is Ascidiacea
Annie: Another one I can't pronounce. Thanks. I'm glad you know what sea squirt is though, Josh. That's, that's very cool. [00:35:00] I think that's just such an amazing approach to go to the bottom of the ocean. Like, we've been mining the soil for antibiotics and antimicrobials for decades, haven't we?
And to try a completely different ecological niche might be kind of the next frontier. So, that's really cool. talking about maybe next frontiers in fungal infections, looking at combating fungal infections from another perspective entirely, Neil, can you share some of your thoughts on, targeting the host immune system as a potential therapeutic approach for fungal infections?
Neil: Thanks, Annie. I think this is really important. So fungal infections are the ultimate opportunists, really.
So as we speak, doing this podcast, in different parts of the world, we're probably all inhaling aspergillus or similar things right now. But hopefully, without going into your medical histories, we've got a reasonably functioning immune system, and it's, not giving us much of a problem. But of course, we know, aspergillus can be deadly to the right host or the wrong host, depending on what, point of view you look at.
always reminds me a bit of, you know, Bill Clinton's famous saying, "It's the economy, stupid," that that's all that really [00:36:00] mattered. When it comes to fungal infections, and you can talk about the organism forever, but ultimately it's the host, stupid. That it's actually the host that's far more important than the organism itself.
' Cause, you know, fit and healthy people don't generally get these infections. It's people who are highly immunosuppressed. So it seems obvious and intuitive that, why don't we target host-directed therapy rather than the organism. Now, I have to say, this is not an area that I work in directly myself.
Neil: It's something that, besides being intuitive that, people in the field have been working on for a long time. and there have been a whole range of small studies looking at different parts of the immune system and different places to try and target it. there was at one point, a kind of trend for looking at, anti-heat shock protein, anti-HSP, antibodies, for example.
MycoGrab was one which seemed to, have its moment in the sun and then disappeared. cytokines are really interesting. So interferon gamma we know is really important in invasive fungal infections, particularly candida cryptococcus. And there have been small kind of phase two trials looking at adding, interferon gamma, and patients seem [00:37:00] to do better.
and it's always got that line that, , at the end of all these studies, need bigger studies. IL-7's been looked at. granulocyte infusions blocking different cytokines. More recently, we've got checkpoint, blockade, which seems really interesting, because we know in patients with severe fungal infection, that upregulates checkpoints, for example, PD-1.
if you can actually blockade that can restore interferon gamma production phagocyte function, at least in models. So there's interest there. So any number of possibilities of where you might want to
target host factors. It's the same story really where it's been small studies, it's been preclinical, it's been theoretical, it's been case series, case reports, or at best maybe a phase two trial, which haven't really gone anywhere.
Neil: And it- it's interesting why, that's happened. the trials have generally been small. They're a very heterogeneous patient group. It's mostly salvage therapy, so it's quite hard to recruit patients for these studies and I think also realistically it's always going to be adjunct to therapy with antifungals rather than [00:38:00] host-directed therapies on its own.
So it's quite hard often to build enough data to get a true effect. But, it's an obvious target We know how, important host factors are here. I think there is some good news and movement on this. , There is a large study in Cryptococcus coming, looking at interferon gamma to build on some small phase two work.
we need more of that, and I think it's often, ignored. It tends to be academic centers where there's a special interest have this in small numbers.
Neil: it's a cliché now, and I've just said every paper ends with the same, "Needs more research," but it really does because in the absence of good antifungals, host factors are just absolutely essential. And I'd be interested in what others think. And, Josh, this is an area of expertise for you and, what your thoughts are on this whole field Out of all of these possibilities, what we should focus on most.
it's incredibly interesting. There's an International Immunotherapy Society for Fungal Diseases which was started just about a year ago with Arturo Casadevall, Frank van de Veerdonk, and then our friend Dimitrios Kontoyiannis, down in Texas. [00:39:00] And they're really looking at this as a very viable way, not in and of itself, but in conjunction with other interventions.
Josh N: as you put it, it's really when you have a dysregulation in the host is when we find people to be most susceptible for these terrible diseases. And if you can harness that knowledge and shift for example interferon gamma or provide antibody, to somebody and change how that interface between that fungus and a host cell are interacting, you can really have a tremendous change.
there are opportunities that we've missed. There was an antibody that Arturo made a long time ago in the '90s that, was shown to be very effective in mitigating cryptococcal meningitis, and it went into a clinical trial, and then it stopped. And it stopped in part because HIV was no longer the threat in the United States that it was during the height of the HIV pandemic.
Josh N: And so again, it gets back to where do you get the funding to advance a [00:40:00] drug or other treatment that may not be used very often? And so that's another struggle that's part of the puzzle that we need to solve. But it's certainly a very interesting area. And I know, Jeniel, you've been at some of the meetings that we've been at too, talking about, how you modify these diseases.
There are other folks like Tobias Holl and Jatin Vyas who are looking at this too. Do you have any other comments on that?
Jeniel: One thing I'd be very excited about to see in the future would be, a fungal vaccine because a lot of these patients, we know might become at risk if we know that they have underlying immune problems.
so that's one area where it'd be really exciting if, we could vaccinate people, before they got their immune suppression or their transplant and prevent, some of the pathogens that way.
and there are some vaccines against fungi, but they're for dermatophyte in horses, so we have no human fungal vaccine.
Josh N: there's some really interesting work that I've been part of looking at making vaccines from extracellular [00:41:00] fungal vesicles. That's an area of work that did not exist before 2006, so it's only a 20-year-old, field. But there's a lot of promise for the future, especially as we continue to learn more and more about some of the basic biology.
As we wrap up, I want to ask our incredible guests, and thank you again, guys, to tell us where they think medical mycology will be in 10 years, and I'm going to start with you, Jeniel. What are you going to be teaching in your Woods Hole course in the future?
Jeniel: so I'll be teaching the Woods Hole course for I, think the next four years, so I guess I won't be teaching in 10 years.
We'll have, new directors by then. but we're really looking at continuing to teach important animal models, trying to incorporate, human tissues. we teach, genetic manipulation of fungi, a lot of cutting-edge imaging techniques, and we're expanding host interactions using cell lines.
and then in the next couple of years, we're hoping to introduce some CRISPR screens that I think will be, fun for, the trainees to learn.
Yeah, I think another area that's interesting is the advances that we [00:42:00] have in organoids and how to look at 3D models and, you know, other models like your tissue sweat model for Candida auris.
Josh N: So lots of opportunities for young and enthusiastic investigators in fungi. How about you, Neil? I know based on your recent publications, you think about the future a lot. what do you have to share with us?
Neil: I think, the future is, brighter than it was, and today's discussion has shown that to some extent with the new drugs.
But I actually think as fascinating as they are, and, delighted as I am that we've got these new drugs, I don't think that's all the answer. I think diagnostics is a really interesting area because diagnostics in mycology, it holds the key to everything else. If you can't diagnose an infection, how can you treat it properly?
And how can you do stewardship properly? because, any of us who work in mycology know this problem. you end up either missing fungal infections you didn't know about or you over-treat because you can't rule it out. But there are interesting things happening in diagnostics. So
certainly, rapid tests are, becoming really important.
We've talked about, Josh, accessibility around the world. So I always take the [00:43:00] cryptococcal antigen as the model. That's kind of the ideal test because it's super sensitive and specific, and it can be used all around the world. There are similar tests now, for example, histoplasma antigen. There are rapid galactoman and even beta-D-glucan tests now, coccidioides antigens, which are going to becoming much more accessible and quicker.
Neil: So that's exciting, and I love a point of care test. but, looking further into the future, we've got AI. You know, that's the buzzword. We can't do a podcast in 2026 without talking about artificial intelligence, and we must not be left behind in mycology because we've been guilty of that in the past.
Where we're going to use that, I'm not quite sure whether that's looking at CT scans and whether we can detect possible or probable fungal infection or looking at histopathology specimens or morphology of fungi using AI is going to be probably more accurate than the human eye kind of thumbing through old textbooks as we do now.
I think the big advance, or at least the one that's exciting me, is, metagenomics. So, this is a, big topic across the world of infection and, here in the UK, and Annie, you've probably come across this already.
Our [00:44:00] national reference laboratory for medical mycology has rolled out a metagenomic DNA capture assay for some of the dimorphic fungi in Cryptococcus, for example. And it's extremely sensitive, the likes of which we've never had before. Interpreting it's difficult because it's a new test, but I think it shows what can be done.
Neil: so I think the future is exciting in terms of molecular methods for diagnosing fungal infection. as with all of these new drugs, new diagnostics, the proof is in the pudding. Will it ultimately lead to better outcomes? and we still have, these fungal infections have a high mortality.
All of these studies we've spoken about have been non-inferiority, not superiority. That last 20, 30% of mortality, which is still far too high, maybe the answer is immunotherapy, maybe the answer is adjunctive therapy, maybe it's combination therapy, maybe it's better diagnostics. The reality is it's probably all of those put together.
But I'm excited about the future of metagenomics. The key is going to be clinical impact, but that's certainly novel and exciting in [00:45:00] mycology.
Annie: Absolutely. And I'm, a bit of an imposter on this call because I'm not a mycologist whereas the three of you are mycologists. But you've made me very excited about the, potential and the future , from diagnostics to new antifungals and host immune response and molecular mycology. So hopefully if there's some, trainees listening to Communique, maybe they can really think about giving, medical mycology a, really good thought as a, subspecialty because it's really kind of undervalued and underappreciated. yeah, you guys can, put the fun back in fungi. Okay, that's the last pun from me, I think.
Josh N: There's not mushroom for more than that.
Annie: No, I think we've, done enough. as we're kind of drawing to a close, do either of you, Jeneil or Neil and Josh as well, have any last messages, about antifungals or, mycology in general that you'd like to get across to our Communique listeners?
Maybe we'll go to Jeneil first.
Jeniel: Yeah. I just want to echo what you said about any trainees that might be listening. I just wanted to mention how amazing it has been to be part of the medical mycology community. It's a really welcoming and [00:46:00] fun community, and as you probably heard, we certainly have a lot of work to do for, prevention and treatment of fungal infections, so trainees should, consider the field
Neil: Yeah, I think it's a really exciting time to get into mycology.
We've had this whole discussion about new drugs. We've got new diagnostics coming through. It's become a WHO priority, so there's lots of exciting work going on, very dynamic in a way it's never been before, but it's also got the advantage that it is a small enough field that, , you're going to get to know people quite well and make those personal connections, which is really quite nice.
So definitely I would encourage people to get involved in mycology. I, think you can make a really nice and interesting career out of it and make a difference to patients, which is ultimately what it's all about. But just one other message, we've spoken about all of these drugs, I think we have to mention antifungal stewardship.
it's a great irony, isn't it? Infectious disease medicine in general is that we want these new drugs, and what's the first thing we do with a new drug is we say to everyone, "You can't use it." Okay? And that's why pharma doesn't like it, because they want to sell lots of it, and we want to stop people using it, but it comes down to stewardship.
That it's all well and good [00:47:00] having new drugs, that's fantastic, but if we don't use them judiciously, , if we don't do stewardship properly, everything we've spoken about today is going to go to waste because we'll get resistance to it quickly.
There's some really good resources out there on antifungal stewardship. the IDSA put out a really good guide about the essential ingredients for an antifungal stewardship program. we've recently done a review of educational resources in antifungal stewardship.
Neil: So there's lots of resources to learn about it and get involved in it. And again, at your institution, if you become the lead or get involved in antifungal stewardship, there's probably not that many other people doing it, so you can make your way quite well in that, but it's really, really important.
And the other thing that's important to realize is that we are encountering new fungal diseases. C. auris is an example. Emergomyces is another. There are, because of what we are doing in our world, going to be even more organisms that we encounter.
Josh N: So there's ongoing work that will have to be done in this area, and it's very exciting.
Annie: Thanks so much again to our [00:48:00] expert guests for a really fascinating discussion, and we've had Janiel Nett from the University of Wisconsin, Madison, USA, and Neil Stone from Hospital for Tropical Diseases and University College London, UK. thank you for listening to Communicable, the CMI Comms podcast. This episode was hosted by Josh Nosanchuk, who's our resident, mycology expert at CMI Comms, based in Michigan, USA, and me, Annie Joseph, in Nottingham, UK, associate editors at CMI Comms, ESCMID's open access journal.
Theme music was composed and conducted by Joseph McDade, and any literature we've discussed today, we'll put in the show notes so, listeners can, find links to those. You can subscribe to Communicable wherever you get your podcasts or find it on ESCMID's website for the CMI Comms journal.
thank you for listening and helping CMI Comms and ESCMID move the conversation in infectious diseases and clinical microbiology further along.
Annie: do you know what? Before I start [00:49:00] this sentence, , how is everybody saying ibre- ibrexafungerp?
.
Annie: I'm gonna sound like an idiot. Neil?
Neil: ibrexafungerp.
Neil: I don't know what they were smoking when they came up with the name ibrexafungerp.
Annie: Okay, that's how I say it.
Annie: So for example, we've got ibrexafungerp which is a novel oral triti- tritipeno- penoid.
Annie: That must be wrong. Neil?
Neil: Triterpenoid.
Annie: Tritipenoid? Triterpenoid?
Neil: Triterpenoid.
Annie: Triterpenoid.
Annie: So for example, we've got ibrexafungerp which is a novel oral tritepa- tri- oh my God,
Annie: Triterpenoid.
[00:50:00]